Re:meat rebrands as Curve to power the next wave of industrial-scale protein biomanufacturing

Curve, the Swedish biotechnology company formerly known as Re:meat, has unveiled its new name and expanded mission to enable scalable, cost-efficient biomanufacturing of proteins across industries. The rebrand, announced today in Malmö, marks a shift from a single focus on cultivated meat to a broader technology platform designed to unlock commercial-scale production in food, health, materials, and cosmetics.

“Scaling biotech is the next industrial revolution – but it demands tools built for this century, not the last,” commented Jacob Schaldemose Peterson, Co-founder & CEO of Curve. “With Curve, our ambition is to unlock scalable biomanufacturing – at cost points that finally make industrial deployment possible.”

While the potential of biomanufacturing is well established, scale remains its greatest bottleneck. Traditional production systems, designed primarily for either low-cost food applications or tightly regulated pharmaceutical environments, struggle to meet the needs of emerging protein markets. Curve’s modular and intelligent production systems are designed to bridge this gap – offering industrial-scale capabilities without the prohibitive costs of pharma-grade setups.

The company’s core technology, called BIOBRIC, is engineered for cost leadership and process agility. According to Curve, the platform can reduce capital expenditure by up to 70%, accelerate process optimization, and enable commercially viable precision fermentation and cell cultivation. The system combines hardware, simulation tools, and real-time process learning to drive efficiency and scalability across different protein applications.

The rebrand underscores Curve’s evolution from a cultivated meat startup into a platform player supporting multiple sectors of the protein economy. “Cost-efficient cultivated meat production has always been the ambition for Re:meat,” said Torbjörn Sahlén, investor and board member at Curve. “However, experience shows that if we focus exclusively on that, we are not maximizing our ability to scale and leave significant potential untapped. This shift – and consequently the name Curve – reflects this strategic opportunity.”

The demand for affordable, safe, and sustainable proteins is accelerating globally, and not just in food. Proteins are emerging as foundational components across industries – from nutrition and healthcare to materials, animal feed, and personal care. Yet, the production infrastructure for these new applications remains outdated and resource-heavy. Curve’s approach seeks to modernize the manufacturing layer of biotech by creating smarter, more flexible systems designed for rapid deployment and economic viability.

“Today’s production systems were never built for these new markets,” Peterson said. “They are resource-heavy, slow to scale, and economically misaligned. To unlock the next era of biotech, we need technology that can produce complex proteins at industrial scale, with minimal cost and environmental impact. Smarter biomanufacturing is how we enable healthier living, greener industries – and a more resilient future.”

Curve is already collaborating with precision fermentation and advanced biotech companies on joint scale-up trials, helping partners optimize strains, media, and processes before licensing its validated systems for industrial use. This collaborative approach is central to the company’s strategy: by integrating early-stage development with scalable hardware and process intelligence, Curve aims to accelerate the path from lab to factory floor.

The company’s BIOBRIC system is part of a new generation of bioreactor technologies emerging to meet the unique needs of industrial biotechnology. Unlike traditional setups, which are often rigid and expensive to adapt, Curve’s modular system is designed for iterative scaling and data-driven optimization. This flexibility allows companies to move from pilot to production faster, reducing both financial and technical barriers.

The name Curve was chosen to symbolize momentum and transformation – reflecting both the company’s growth trajectory and its goal of “bending the cost curve” for protein biomanufacturing. The rebrand also signifies a broader invitation to industry partners: to co-develop scalable, intelligent systems that make biotech production economically and environmentally sustainable.

Headquartered in Malmö, Curve is part of Sweden’s growing ecosystem of deep-tech companies focused on sustainable production technologies. Its integrated model – combining engineering, software, and bioprocess expertise – positions it to serve a diverse range of industrial biotech markets.

As Peterson put it, the mission is simple but ambitious: “To make biomanufacturing commercially viable at scale. That’s how we move from potential to real impact.”